PF 4531083
Alternative Names: PF-04531083Latest Information Update: 30 Jul 2012
At a glance
- Originator Pfizer
- Class Analgesics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Pain; Postoperative pain
Most Recent Events
- 10 Jul 2012 Pfizer terminates phase II trial in Postoperative pain in USA (NCT01512160)
- 22 May 2012 Pfizer completes enrolment in its phase II trial for Postoperative pain in USA (NCT01512160)
- 10 May 2012 Discontinued - Phase-I for Pain in Belgium (PO)